Clinical Trials
32 trialsFIGHT-210
Incyte Corporation
A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer
Faeth Therapeutics
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
Stanford University
EDO-S101
Mundipharma Research Limited
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
National Cancer Institute (NCI)
PIL
Augusta University
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
Pfizer
Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
RAIN
Rain Oncology Inc
Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
Big Ten Cancer Research Consortium
Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer
Fox Chase Cancer Center
TRINITY
AbbVie
Cabozantinib in Advanced Solid Malignancies
Massachusetts General Hospital
NSCLC
Clovis Oncology, Inc.
Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients
Clovis Oncology, Inc.
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
Clovis Oncology, Inc.
EGFR
Clovis Oncology, Inc.
Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer
Dana-Farber Cancer Institute
PRIMAL
Halozyme Therapeutics
Proton Beam Re-Irradiation in Thoracic Cancers
University of Washington
EMPRESS
Medtronic - MITG
Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT)
M.D. Anderson Cancer Center
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
MEI Pharma, Inc.
AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer
University of Pittsburgh
Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem
H. Lee Moffitt Cancer Center and Research Institute
An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma
Sanofi
Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib
Memorial Sloan Kettering Cancer Center
MDX1106-01
Bristol-Myers Squibb
Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer
SCRI Development Innovations, LLC
ReGaiN
Chonnam National University Hospital
Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer
Eli Lilly and Company
Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)
Sanofi